Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 6

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Mantle cell lymphoma recurrent+1

Recruiting

A study to compare glofitamab against a drug combination for patients with relapsed or refractory mantle cell lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

Essential thrombocythaemia

Recruiting

A study to evaluate the effectiveness and safety of iadademstat in adults with essential thrombocythemia who do not respond well to or cannot tolerate hydroxyurea

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Iadademstat
  • Sponsor:Oryzon Genomics S.A.

Acute myeloid leukaemia

Recruiting

A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Fundacion PETHEMA

Mantle cell lymphoma

Recruiting

A study to evaluate the effectiveness of pirtobrutinib in elderly and frail patients with mantle cell lymphoma who have not yet received treatment.

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Fondazione Italiana Linfomi Ets

Acute myeloid leukaemia

Recruiting

Study of Revumenib, Cytarabine, and Fludarabine in Children with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Pediatric Research International GmbH

Acute myeloid leukaemia

Recruiting

Study of ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Kura Oncology Inc.

Autoimmune haemolytic anaemia+1

Recruiting

A study to evaluate the safety and effectiveness of tafasitamab in adults with autoimmune thrombocytopenia or autoimmune hemolytic anemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tafasitamab
  • Sponsor:Incyte Corp.

Plasma cell myeloma

Recruiting

A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Acute leukaemia

Recruiting

A study of enzomenib in adult patients with relapsed or refractory acute leukemia, including those with MLL rearrangement or NPM1 mutation.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Sumitomo Pharma America Inc.

Thalassaemia beta+1

Recruiting

A Study of Gene Therapy Using Modified Stem Cells for Patients with Transfusion-Dependent Beta-Thalassemia Who Need Regular Blood Transfusions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Fondazione Telethon Ets

Von Willebrand's disease

Recruiting

A Study of VGA039 to Prevent Bleeding in Teenagers and Adults with von Willebrand Disease Who Have Not Used Regular Preventive Treatment Before

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:VGA039
  • Sponsor:Vega Therapeutics Inc.

B-cell lymphoma

Recruiting

A study comparing AZD0486 after reduced chemotherapy versus standard chemotherapy in older or unfit patients with newly diagnosed large B-cell lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.